Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth Reuters - 25 Apr 2024 Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth ... More
Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration Genetic Engineering & Biotechnology News - 25 Apr 2024 Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration ... More
Regeneron and Mammoth team up to develop gene editing therapies Pharmaceutical Technology - 26 Apr 2024 Regeneron and Mammoth team up to develop gene editing therapies ... More
Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) Bloomberg Law - 26 Apr 2024 Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) ... More
Sales of Roche's juggernaut Vabysmo rout the analyst consensus FiercePharma - 24 Apr 2024 Sales of Roche's juggernaut Vabysmo rout the analyst consensus ... More
AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study XM - 25 Apr 2024 AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study ... More
Regeneron and Mammoth announce gene editing partnership worth $370m per target PMLiVE - 26 Apr 2024 Regeneron and Mammoth announce gene editing partnership worth $370m per target ... More
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines MedCity News - 25 Apr 2024 Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines ... More
Regeneron signs Mammoth gene editing deal worth $100M upfront Fierce Biotech - 25 Apr 2024 Regeneron signs Mammoth gene editing deal worth $100M upfront ... More
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors MarketWatch - 26 Apr 2024 Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors ... More
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery BioSpace - 25 Apr 2024 Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery ... More
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch Investopedia - 11 Apr 2024 Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch ... More
Regeneron inks $100M deal to develop gene-editing therapies Crain's New York Business - 26 Apr 2024 Regeneron inks $100M deal to develop gene-editing therapies ... More
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study Reuters - 25 Apr 2024 AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study ... More
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent FiercePharma - 26 Apr 2024 Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent ... More
Regeneron hit with FDA rejection for blood cancer therapy Pharmaceutical Technology - 26 Mar 2024 Regeneron hit with FDA rejection for blood cancer therapy ... More
Regeneron to defend against DOJ complaint on drug-price manipulation Reuters - 15 Apr 2024 Regeneron to defend against DOJ complaint on drug-price manipulation ... More
Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare FiercePharma - 11 Apr 2024 Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare ... More
US accuses Regeneron of fraudulent price reporting for eye drug Reuters - 10 Apr 2024 US accuses Regeneron of fraudulent price reporting for eye drug ... More